ArticleESC heart failure2023
Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan.
Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.Blood advances · 2026Guideline
- Diagnostic Performance Evaluation of Clinical and Artificial Intelligence Risk Models in Patients Referred for Cardiac Amyloidosis Testing.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2026Article
- Four Key Challenges After a Decade of Consecutive Paradigm Shifts in Wild-Type Transthyretin Amyloid Cardiomyopathy: From Rarely Found to Never Missed.Circulation reports · 2026Review
- Investigating transthyretin variants H88R and I107V in amyloid priming: From destabilization to complete dissociation.The FEBS journal · 2026Article
- Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B.JACC. Asia · 2026Article
- Clinical features of systemic amyloidosis: a scoping review.Blood advances · 2026Article
- The Progressive Cardiac Uptake ofInternal medicine (Tokyo, Japan) · 2026Article
- A No-Code, Guideline-Based Custom GPT Outperforms Cardiologists in Response Quality for Cardiac Amyloidosis.JACC. Advances · 2026Article
- Better Outcomes After Initiation of Disease-Modifying Therapy in Patients with Transthyretin Cardiac Amyloidosis.Journal of clinical medicine · 2026Article
- The Evaluation of Relative Left Ventricular Wall Thickness on Echocardiography for the Diagnosis of ATTR Cardiac Amyloidosis.Life (Basel, Switzerland) · 2026Article
- Transthyretin amyloid cardiomyopathy-new data regarding epidemiology, diagnosis, and treatment.ESC heart failure · 2026Article
- Global Burden of Cardiac Amyloidosis in Heart Failure: A Systematic Review and Meta-Analysis.Research square · 2026Article
- Predicting short-term composite outcome risk in heart failure patients using a machine learning model incorporating UHR: a retrospective cohort study.Frontiers in nutrition · 2026Article
- The phenotypic landscape of p.Ala117Ser transthyretin amyloidosis: distinct clinical profiles and outcomes versus wild-type ATTR.BMC cardiovascular disorders · 2025Observational
- Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022-2025.Journal of cardiovascular development and disease · 2025Review
- Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction.ESC heart failure · 2025Article
- First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia.ESC heart failure · 2024Article
- Transthyretin amyloidosis prevalence and characteristics in Korean patients with heart failure with preserved or mildly reduced ejection fractions.Scientific reports · 2024Article
- Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan.ESC heart failure · 2023Article
- Molecular Research on Amyloidosis.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHeart failure with preserved ejection fraction (HFpEF), which is caused by wide various conditions, has become a major public health problem. Transthyretin amyloid cardiomyopathy (ATTR-CM), which is thought to be an underdiagnosed disease, can cause HFpEF. Non-invasive diagnosis using METHODS AND
resultsThis study was a multicentre, prospective, observational study conducted in Japan. We enrolled 373 patients with HFpEF [left ventricular (LV) ejection fraction ≥50%] aged ≥65 years who were admitted to the department of cardiology from September 2018 to January 2022. A
conclusionsATTR-CM is an underdiagnosed disease with a significant prevalence in Japanese patients with HFpEF. This study showed that results of examinations for ATTR-CM patients appear to be worse than those for non-ATTR-CM patients, but clinical severities of heart failure as assessed by the NYHA functional classification are similar in ATTR-CM and non-ATTR-CM patients, and the clinical overlap between ATTR-CM and non-ATTR-CM is high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.